A ferrocenyl pyridine-based Ru(II) arene complex capable of generating center dot OH and O-1(2) along with photoinduced ligand dissociation

作者：Wang, Tianji; Zhou, Qianxiong^*; Zhang, Yangyang; Zheng, Yue; Wang, Weibo; Hou, Yuanjun; Jiang, Guoyu; Cheng, Xuexin; Wang, Xuesong^*

来源：RSC Advances, 2016, 6(51): 45652-45659.

DOI：10.1039/c6ra05182k

• POST-GENOMIC ERA
• PHOTODYNAMIC THERAPY
• SINGLET OXYGEN
• BIOLOGICAL EVALUATION
• RUTHENIUM COMPLEXES
• ANTICANCER AGENTS
• DNA PHOTOCLEAVAGE
• ANTITUMOR DRUGS
• LIGHT
• DERIVATIVES

Photoactivated chemotherapy (PACT) and photodynamic therapy (PDT) are two types of cancer treatment modalities that rely on photoinduced ligand dissociation and photosensitized or photocatalyzed reactive oxygen species (ROS) generation to realize anticancer activities with high selectivity, respectively. In this study, a novel Ru complex, [(p-cym)Ru(bpy)(py-Fc)](2+) (1), where p-cym = para-cymene, bpy = 2,2'-bipyridine, and py-Fc = 4-pyridyl ferrocene, was demonstrated to show dual activity from PACT and PDT. 1 has a long-wavelength absorption band extending to 600 nm and can generate both hydroxyl radicals (center dot OH) and singlet oxygen (O-1(2)) along with photoinduced monodentate ligand dissociation. As a result, 1 displays DNA photocleavage activity as well as phototoxicity against human ovarian adenocarcinoma cells SKOV3 and human lung adenocarcinoma cells A549. The underlying mechanisms were discussed by comparing the photophysical, photochemical, and photobiological properties of 1 with that of [(p-cym)Ru(bpy)(py)](2+) (2, py = pyridine) and free py-Fc, providing guidelines for developing new photoactivated metallodrugs with multiple functions.

• 出版日期2016
• 单位中国科学院理化技术研究所; 中国科学院大学